Golden Ticket (The Office)

Moving iMage Technologies Announces Golden Ticket Cinemas Selects LEA Amplifiers for its Immersive Auditoriums

Retrieved on: 
Wednesday, November 8, 2023
Software, Audio, Video, Hardware, Electronic Design Automation, Engineering, Technology, Manufacturing, Mobile, Wireless, LEA, NYSE, Golden Ticket (The Office), DSP, Digital signal, High energy X-ray imaging technology, Digital signal processing, Golden Ticket, GTC, Film industry, Massachusetts Institute of Technology

Moving iMage Technologies (NYSE American: MITQ) ("MiT"), a leading technology and services company for cinema, Esports, stadiums, arenas and other out-of-home entertainment venues, announced the Company’s new customer, Golden Ticket Cinemas (GTC) selected LEA Professional power amplifiers for its new immersive auditoriums in Greenville, NC and Greensboro, NC.

Key Points: 
  • Moving iMage Technologies (NYSE American: MITQ) ("MiT"), a leading technology and services company for cinema, Esports, stadiums, arenas and other out-of-home entertainment venues, announced the Company’s new customer, Golden Ticket Cinemas (GTC) selected LEA Professional power amplifiers for its new immersive auditoriums in Greenville, NC and Greensboro, NC.
  • “Golden Ticket Cinemas entered a growth phase as part of its post-pandemic strategy, turning to MiT to help rapidly bring online three new locations,” said Ben Stanton, senior director of sales at MiT.
  • They continually provided Golden Ticket with up-to-date options that met its performance and budget requirements, and that included LEA Professional," said Scott Robinson, vice president of sales, LEA Professional.
  • LEA Professional Connect Series amplifiers deliver a total of 10,000 watts and 20,000 watts of total power to Greensboro & Greenville, respectively.

LabCentral Ignite Launches Third Annual Golden Ticket Contest

Retrieved on: 
Monday, May 15, 2023
Amgen, Novartis Institute for Tropical Diseases, First Citizens BancShares, Biomedical Research, Senior, Face, Stroke, Process, Silicon Valley Bank, Cancer, Golden Ticket (The Office), Kendall Square, Bristol Myers Squibb, Nanomedicine, Science, Thought, Interest, Harmony, Silicon, LabCentral, MA, Golden Ticket, Wilson Sonsini Goodrich & Rosati, BMS, B cell, Health, Therapy, Amusement park, Pharmaceutical industry, Creative industries, Film industry, Takeda, Pfizer

CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ -- LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched its third annual Golden Ticket contest that is designed to support diverse, underrepresented biotech entrepreneurs who are using innovative science to solve problems for human health. Interested entrepreneurs and scientists can visit LabCentral Ignite Golden Tickets for a program overview, eligibility rules, and to apply.

Key Points: 
  • Interested entrepreneurs and scientists can visit LabCentral Ignite Golden Tickets for a program overview, eligibility rules, and to apply.
  • "Bristol Myers Squibb is delighted to partner with LabCentral for a second year by supporting the LabCentral Ignite Golden Ticket contest," said Emma Lees, Senior Vice President, Oncology Discovery and Site Head for BMS Cambridge R&D.
  • In addition, the inaugural LabCentral Ignite Golden Ticket winners from 2021 each received significant investment last year, including a $6 million seed round for Harmony and a $10 million Series A for Nanopath with a lead investor coming through LabCentral Ignite.
  • A select number of finalists will receive access to coaching and will be invited to present at a pitch event on September 19th where the eight winning companies will be awarded LabCentral Ignite Golden Tickets.

Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs

Retrieved on: 
Tuesday, April 18, 2023
Benefit corporation, Golden Ticket (The Office), Research, Mentorship, Science, Entrepreneurship, Patient, Rare, Creative Biolabs, Disease, Pharmaceutical industry, Chiesi Farmaceutici

Sponsorship leverages BioLabs' coworking lab and office facilities to empower science and innovation in rare diseases, pulmonary diseases and specialty care.

Key Points: 
  • Sponsorship leverages BioLabs' coworking lab and office facilities to empower science and innovation in rare diseases, pulmonary diseases and specialty care.
  • BOSTON, April 18, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced a U.S. Networkwide Sponsorship of BioInnovation Labs (BioLabs), the leading developer and operator of life science coworking spaces with 12 active facilities and a growing network in the U.S. and internationally.
  • "As a family business, and as a certified Benefit Corporation, we have a long history of commitment to the rare disease community and will continue to reinvest in scientific research and innovation," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
  • U.S. Networkwide Sponsorship of BioLabs will allow Chiesi to have access to sponsored sites across the country.

Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson’s Disease at Michael J. Fox Foundation Annual Conference

Retrieved on: 
Thursday, October 13, 2022
Neurology, Clinical Trials, Philanthropy, Other Health, Biotechnology, Fund Raising, Pharmaceutical, Health, Foundation, Other Philanthropy, Lewy body, Pharmacology, Parkinson, Disease, Therapy, PD, Conference, Lucy, LabCentral, Bristol Myers Squibb, Parkinson's disease, Rett syndrome, Pivotal, Neuron, Drug discovery, The Michael J. Fox Foundation, Health, Mitochondrion, Degenerative disease, CEO, Golden Ticket (The Office), Research, ETC, Genetics, ATP, Death, Metabolism, Lists of diseases, Central nervous system, Biomarker, Pharmaceutical industry, Engine, Lewy, Biogen

Fox Foundation's 14th annual Parkinson's Disease Therapeutics Conference on October 13, 2022, in New York City.

Key Points: 
  • Fox Foundation's 14th annual Parkinson's Disease Therapeutics Conference on October 13, 2022, in New York City.
  • We have demonstrated that our compounds can rescue neurons in cellular models of Parkinsons disease, validating our therapeutic approach.
  • "Lucy Therapeutics wants to create a world in which mitochondrial-involved neurological diseases like Parkinsons or Rett syndrome can be halted when diagnosed, said Amy Ripka, Ph.D., founder and CEO of Lucy Therapeutics.
  • Fox Foundation for Parkinsons Research , Lucy Therapeutics has received support tallying $24 million as of October 2022, from Pivotal bioVenture Partners, Safar Partners, The Engine and the Massachusetts Life Science Center.

GOLDEN TRAIL SERIES: MADEIRA HOSTS THE FINAL OF THE TRAIL WORLD CUP

Retrieved on: 
Thursday, October 13, 2022
News, ELITE, Man, Golden Ticket (The Office), Woman, OPEN, Athlete, Fireworks

From 26th to 31st October on the island of Madeira, the top 30 men and top 30 women in the general rankings will race at the Madeira Ocean&Trails, the grand final of the Golden Trail Series after the season's six legs.

Key Points: 
  • From 26th to 31st October on the island of Madeira, the top 30 men and top 30 women in the general rankings will race at the Madeira Ocean&Trails, the grand final of the Golden Trail Series after the season's six legs.
  • One final 5-stage test where these athletes can earn precious points to win the title of the planet's best trail runner.
  • Prizes will be awarded daily, recognising the athletes' performances and representing a total of 178,500 euros over the entire final.
  • Tune in at 8pm (GMT+1) after each stage to get all the news about this great world final: goldentrailseries.com/gttv/
    All the information you need on: https://madeiragtwsfinal.com

GOLDEN TRAIL SERIES: MADEIRA HOSTS THE FINAL OF THE TRAIL WORLD CUP

Retrieved on: 
Thursday, October 13, 2022
News, ELITE, Man, Golden Ticket (The Office), Woman, OPEN, Athlete, Fireworks

From 26th to 31st October on the island of Madeira, the top 30 men and top 30 women in the general rankings will race at the Madeira Ocean&Trails, the grand final of the Golden Trail Series after the season's six legs.

Key Points: 
  • From 26th to 31st October on the island of Madeira, the top 30 men and top 30 women in the general rankings will race at the Madeira Ocean&Trails, the grand final of the Golden Trail Series after the season's six legs.
  • One final 5-stage test where these athletes can earn precious points to win the title of the planet's best trail runner.
  • Prizes will be awarded daily, recognising the athletes' performances and representing a total of 178,500 euros over the entire final.
  • Tune in at 8pm (GMT+1) after each stage to get all the news about this great world final: goldentrailseries.com/gttv/
    All the information you need on: https://madeiragtwsfinal.com

Ethereum & Decentral Founder Anthony Di Iorio Announces Andiami: The Quest for Liberty's Global Unveiling Event on November 7 in Toronto

Retrieved on: 
Wednesday, October 5, 2022
Bitcoin, Movement, Metro Toronto Convention Centre, Web3, Anthony Di Iorio, Empowerment, Golden Ticket, Liberty, Blockchain, Don, CEO, Ecosystem, Golden Ticket (The Office), Basement Jaxx vs. Metropole Orkest, Airline, Cryptocurrency, Decentralized application, Ethereum, Web 2.0

TORONTO, Oct. 5, 2022 /PRNewswire/ -- Andiami: The Quest for Liberty will be unveiled on the evening of November 7, 2022, at the Metro Toronto Convention Centre, Ethereum, Decentral, & Jaxx Founder Anthony Di Iorio announced today. Andiami is an upcoming global tech project designed to power a user-controlled internet while complementing & assisting leading decentralized technologies such as Bitcoin, Ethereum, and others.

Key Points: 
  • TORONTO, Oct. 5, 2022 /PRNewswire/ -- Andiami: The Quest for Liberty will be unveiled on the evening of November 7, 2022, at the Metro Toronto Convention Centre, Ethereum, Decentral, & Jaxx Founder Anthony Di Iorio announced today.
  • The special Golden Tickets will also include attendees in a series of giveaways & prizes at the event.
  • In late 2013, Anthony Di Iorio funded & co-founded Ethereum, the decentralized smart contract platform that hit $500 billion in market cap at its peak.
  • Decentral recently announced Andiami: The Quest for Liberty , an upcoming global tech project.

Ethereum & Decentral Founder Anthony Di Iorio Announces Andiami: The Quest for Liberty's Global Unveiling Event on November 7 in Toronto

Retrieved on: 
Wednesday, October 5, 2022
Bitcoin, Movement, Metro Toronto Convention Centre, Web3, Anthony Di Iorio, Multimedia, Empowerment, Golden Ticket, Liberty, Blockchain, Don, CEO, Ecosystem, Golden Ticket (The Office), Basement Jaxx, Airline, Cryptocurrency, Decentralized application, Ethereum, Web 2.0

TORONTO, Oct. 5, 2022 /PRNewswire/ - Andiami: The Quest for Liberty will be unveiled on the evening of November 7, 2022, at the Metro Toronto Convention Centre, Ethereum, Decentral, & Jaxx Founder Anthony Di Iorio announced today.

Key Points: 
  • TORONTO, Oct. 5, 2022 /PRNewswire/ - Andiami: The Quest for Liberty will be unveiled on the evening of November 7, 2022, at the Metro Toronto Convention Centre, Ethereum, Decentral, & Jaxx Founder Anthony Di Iorio announced today.
  • The special Golden Tickets will also include attendees in a series of giveaways & prizes at the event.
  • In late 2013, Anthony Di Iorio funded & co-founded Ethereum, the decentralized smart contract platform that hit $500 billion in market cap at its peak.
  • Decentral recently announced Andiami: The Quest for Liberty , an upcoming global tech project.

Culinary Student Earns Career Win With World Food Champion Title

Retrieved on: 
Monday, May 9, 2022
Titan, Cream, Honey, Caviar, Blue crab, Lake Murray, The Final Table, Dumpling, University, Twitter, Student, Bass, World Food Championships, GLOBE, Challenge One, Certification, Family, Quail, Food, Main, Saluda Dam, Facebook, Golden Ticket, Dallas College, News, City, Horseshoe sandwich, Restaurant, Golden Ticket (The Office), WFC, Burger, Uranium, Fast food, Seafood, Instagram

The rookie WFC competitor conquered multiple challenges against 30 of the best chefs from around the globe, earning him the title of 2021 World Chef Champion.

Key Points: 
  • The rookie WFC competitor conquered multiple challenges against 30 of the best chefs from around the globe, earning him the title of 2021 World Chef Champion.
  • The culinary prodigy is now the reigning World Food Champion, 2021 World Chef Champion and a winner of more than $107,000.
  • Stay up-to-date on all culinary competition news, by following the World Food Championships on Twitter (@WorldFoodChamp), Facebook and Instagram (@WorldFoodChampionships).
  • The World Food Championships (WFC) is the highest stakes food competition in the world.

Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation

Retrieved on: 
Monday, April 11, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Rett syndrome, Mitochondrion, Therapy, Lists of diseases, Population, Bristol Myers Squibb, MJFF, Retirement, Peripheral nervous system, HIV disease progression rates, Coronavirus Scientific Advisory Board (Turkey), CNS, Research, Doctor of Philosophy, Medtronic, Pathology, The Michael J. Fox Foundation, NIH Intramural Research Program, Incidence, Conference, Parkinson's disease, CEO, Golden Ticket (The Office), Technology, Biology, 96th Street station (IND Eighth Avenue Line), Time, LabCentral, Gene, Drug discovery, Sanofi, Patient, Disease, MIT, Pharmaceutical industry, Engine, Biogen, Lundbeck

Lucy Therapeutics (LucyTx), a biotech with a unifying mitochondrial platform, today announced it secured funding from The Michael J.

Key Points: 
  • Lucy Therapeutics (LucyTx), a biotech with a unifying mitochondrial platform, today announced it secured funding from The Michael J.
  • Fox Foundation for Parkinsons Research (MJFF), the largest nonprofit funder of Parkinson's disease research.
  • The grant, valued at $4.9 million, will be used for continued investment into LucyTxs mitochondrial platform, including the development of potential novel medicines.
  • This additional capital will accelerate LucyTxs mission to advance therapeutics for CNS diseases through focus on disease-bottleneck targets rather than genetically implicated targets.